Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 117 of the 120 references it cites were found in a registry or an index.

The Road towards Gene Therapy for X-Linked Juvenile Retinoschisis: A Systematic Review of Preclinical Gene Therapy in Cell-Based and Rodent Models of XLRS

Open access
van der Veen, Isa, Heredero Berzal, Andrea, Koster, Céline, ten Asbroek, Anneloor L. M. A., Bergen, Arthur A., Boon, Camiel J. F. · 2024 · International Journal of Molecular Sciences

Abstract

X-linked juvenile retinoschisis (XLRS) is an early-onset progressive inherited retinopathy affecting males. It is characterized by abnormalities in the macula, with formation of cystoid retinal cavities, frequently accompanied by splitting of the retinal layers, impaired synaptic transmission of visual signals, and associated loss of visual acuity. XLRS is caused by loss-of-function mutations in the retinoschisin gene located on the X chromosome (RS1, MIM 30083). While proof-of-concept studies for gene augmentation therapy have been promising in in vitro and rodent models, clinical trials in XLRS patients have not been successful thus far. We performed a systematic literature investigation using search strings related to XLRS and gene therapy in in vivo and in vitro models. Three rounds of screening (title/abstract, full text and qualitative) were performed by two independent reviewers until consensus was reached. Characteristics related to study design and intervention were extracted from all studies. Results were divided into studies using (1) viral and (2) non-viral therapies. All in vivo rodent studies that used viral vectors were assessed for quality and risk of bias using the SYRCLE’s risk-of-bias tool. Studies using alternative and non-viral delivery techniques, either in vivo or in vitro, were extracted and reviewed qualitatively, given the diverse and dispersed nature of the information. For in-depth analysis of in vivo studies using viral vectors, outcome data for optical coherence tomography (OCT), immunohistopathology and electroretinography (ERG) were extracted. Meta-analyses were performed on the effect of recombinant adeno-associated viral vector (AAV)-mediated gene augmentation therapies on a- and b-wave amplitude as well as the ratio between b- and a-wave amplitudes (b/a-ratio) extracted from ERG data. Subgroup analyses and meta-regression were performed for model, dose, age at injection, follow-up time point and delivery method. Between-study heterogeneity was assessed with a Chi-square test of homogeneity (I2). We identified 25 studies that target RS1 and met our search string. A total of 19 of these studies reported rodent viral methods in vivo. Six of the 25 studies used non-viral or alternative delivery methods, either in vitro or in vivo. Of these, five studies described non-viral methods and one study described an alternative delivery method. The 19 aforementioned in vivo studies were assessed for risk of bias and quality assessments and showed inconsistency in reporting. This resulted in an unclear risk of bias in most included studies. All 19 studies used AAVs to deliver intact human or murine RS1 in rodent models for XLRS. Meta-analyses of a-wave amplitude, b-wave amplitude, and b/a-ratio showed that, overall, AAV-mediated gene augmentation therapy significantly ameliorated the disease phenotype on these parameters. Subgroup analyses and meta-regression showed significant correlations between b-wave amplitude effect size and dose, although between-study heterogeneity was high. This systematic review reiterates the high potential for gene therapy in XLRS, while highlighting the importance of careful preclinical study design and reporting. The establishment of a systematic approach in these studies is essential to effectively translate this knowledge into novel and improved treatment alternatives.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms25021267

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic structure representing the retinoschisin (RS1) gene (A), protein diagram (B), the quaternary structure of the protein (C), and hallmarks of X-linked juvenile retinoschisis (XLRS) (D). (A) (Adapted from Hahn et al. [4]). An overview of RS1 shows the localization and variants within the gene. Colored boxes represent the six exons, and the numbers within the boxes represent their size in nucleotides. The type of variant is presented in the legend, and the frequency and distribution are described within the gene structure. Splice site (n = 38), missense (n = 101), and deletion variants (n = 11) are the three most common variants. (B) Overview of the RS1 protein, featuring the signal peptide domain, the RS1 domain, the discoidin domain and the C-terminal domain. (C) The top and side view of the octamer and double octamer. (D) Fundus photograph of a 35-year old patient with a hemizygous c.428A > T p.(Asp143Val) mutation in the RS1 gene patient with XLRS, and optical coherence tomography image showing macular schisis (asterisk) in this patient with XLRS.
Figure 1 Schematic structure representing the retinoschisin (RS1) gene (A), protein diagram (B), the quaternary structure of the protein (C), and hallmarks of X-linked juvenile retinoschisis (XLRS) (D). (A) (Adapted from Hahn et al. [4]). An overview of RS1 shows the localization and variants within the gene. Colored boxes represent the six exons, and the numbers within the boxes represent their size in nucleotides. The type of variant is presented in the legend, and the frequency and distribution are described within the gene structure. Splice site (n = 38), missense (n = 101), and deletion variants (n = 11) are the three most common variants. (B) Overview of the RS1 protein, featuring the signal peptide domain, the RS1 domain, the discoidin domain and the C-terminal domain. (C) The top and side view of the octamer and double octamer. (D) Fundus photograph of a 35-year old patient with a hemizygous c.428A > T p.(Asp143Val) mutation in the RS1 gene patient with XLRS, and optical coherence tomography image showing macular schisis (asterisk) in this patient with XLRS.CC BY · PubMed Central
Figure 2 Flowchart outlining the screening and selection process. The selection process was performed through the following stages: identification, screening, eligibility criteria and meta-analysis. Taken together, 3983 studies were identified in the first stage, and after removing duplicates, 2946 studies were included in the screening phase. After title and abstract screening, 77 studies were included. After full-text screening, 25 studies were included, split into 19 studies describing viral methods in in vivo models, and 6 studies describing non-viral and alternative delivery methods in vitro and in vivo. After the second eligibility stage, 19 studies using viral methods were eligible for quantitative analysis. For meta-analysis, seven studies were included for b-wave amplitude, four studies for a-wave amplitude and three studies for the ratio between b- and a-wave amplitudes (b/a-ratio). Four studies were not included in any meta-analysis.
Figure 2 Flowchart outlining the screening and selection process. The selection process was performed through the following stages: identification, screening, eligibility criteria and meta-analysis. Taken together, 3983 studies were identified in the first stage, and after removing duplicates, 2946 studies were included in the screening phase. After title and abstract screening, 77 studies were included. After full-text screening, 25 studies were included, split into 19 studies describing viral methods in in vivo models, and 6 studies describing non-viral and alternative delivery methods in vitro and in vivo. After the second eligibility stage, 19 studies using viral methods were eligible for quantitative analysis. For meta-analysis, seven studies were included for b-wave amplitude, four studies for a-wave amplitude and three studies for the ratio between b- and a-wave amplitudes (b/a-ratio). Four studies were not included in any meta-analysis.CC BY · PubMed Central
Figure 3 All in vivo studies were assessed on their risk of bias using the SYRCLE tool [69]. (A) The studies were assessed on whether any information was provided about ethical approval, conflicts of interest, calculation of sample sizes, blinding, or randomization. (B) The studies were assessed on possible risk of selection, performance, detection, outcome reporting, attrition and other biases. When the contralateral eye was used as the (internal) control, questions for random housing and allocation concealment were answered with not-applicable (N/A). Most studies received an unclear risk-of-bias score, due to a lack of reporting of essential quality indicators.
Figure 3 All in vivo studies were assessed on their risk of bias using the SYRCLE tool [69]. (A) The studies were assessed on whether any information was provided about ethical approval, conflicts of interest, calculation of sample sizes, blinding, or randomization. (B) The studies were assessed on possible risk of selection, performance, detection, outcome reporting, attrition and other biases. When the contralateral eye was used as the (internal) control, questions for random housing and allocation concealment were answered with not-applicable (N/A). Most studies received an unclear risk-of-bias score, due to a lack of reporting of essential quality indicators.CC BY · PubMed Central
Figure 4 Therapy characteristics of adeno-associated viral vector-mediated (AAV) gene augmentation therapies in included studies. The total number of experimental groups varies per parameter, as some studies tested multiple versions of the same parameter. (A) A spectrum of AAV types was used. The total number of experimental groups was 23. (B) The majority (67%) delivered the treatment by intravitreal injection. (C) Injection volumes ranged from 1 to 2 µL, although 1 µL was most commonly used (55%). (D) A number of publications reported different total doses of virus delivered to the eye (viral genomes/eye), but the majority chose a titer >4 × 109 vg/eye. The dotted line indicates the median. (E) The animals were treated at variable ages (5 days–7 months), although most were treated before one month of age (median: three weeks; dotted line). scRS/IRBP = modified RS promoter coupled with an interphotoreceptor retinoid-binding protein enhancer; CMV = cytomegalovirus promoter, hRSp4 = a complex consisting of RS1 promoter, human RS1 cDNA with a truncated first intron, human beta-globin polyadenylation site, and AAV2 inverted terminal repeats; shH10 = AAV subtype derived from AAV6; CAG = promoter element consisting of CMV early enhancer, rabbit beta-globin splice adapter, and the promoter, first intron and exon of CB; CB = chicken beta-actin; RS1 = retinoschisin; hRS1 = human RS1; rho = rhodopsin; mOP = mouse opsin; Rs1h = rodent homolog to RS1; 2tYF = AAV subtype with three tyrosine residues mutated to phenylalanine on the AAV2 capsid surface; rAAV2/2-Y444F = AAV subtype with a single Y mutated to F on the AAV2 capsid surface; mini-mGlu6 = a shortened version of the ON bipolar cell-specific promoter mGlu6; Ple155 = a human-DNA MiniPromoter specific to ON bipolar cells; SRI = subretinal injection; IVI = intravitreal injection; NR = not reported.
Figure 4 Therapy characteristics of adeno-associated viral vector-mediated (AAV) gene augmentation therapies in included studies. The total number of experimental groups varies per parameter, as some studies tested multiple versions of the same parameter. (A) A spectrum of AAV types was used. The total number of experimental groups was 23. (B) The majority (67%) delivered the treatment by intravitreal injection. (C) Injection volumes ranged from 1 to 2 µL, although 1 µL was most commonly used (55%). (D) A number of publications reported different total doses of virus delivered to the eye (viral genomes/eye), but the majority chose a titer >4 × 109 vg/eye. The dotted line indicates the median. (E) The animals were treated at variable ages (5 days–7 months), although most were treated before one month of age (median: three weeks; dotted line). scRS/IRBP = modified RS promoter coupled with an interphotoreceptor retinoid-binding protein enhancer; CMV = cytomegalovirus promoter, hRSp4 = a complex consisting of RS1 promoter, human RS1 cDNA with a truncated first intron, human beta-globin polyadenylation site, and AAV2 inverted terminal repeats; shH10 = AAV subtype derived from AAV6; CAG = promoter element consisting of CMV early enhancer, rabbit beta-globin splice adapter, and the promoter, first intron and exon of CB; CB = chicken beta-actin; RS1 = retinoschisin; hRS1 = human RS1; rho = rhodopsin; mOP = mouse opsin; Rs1h = rodent homolog to RS1; 2tYF = AAV subtype with three tyrosine residues mutated to phenylalanine on the AAV2 capsid surface; rAAV2/2-Y444F = AAV subtype with a single Y mutated to F on the AAV2 capsid surface; mini-mGlu6 = a shortened version of the ON bipolar cell-specific promoter mGlu6; Ple155 = a human-DNA MiniPromoter specific to ON bipolar cells; SRI = subretinal injection; IVI = intravitreal injection; NR = not reported.CC BY · PubMed Central
Figure 5 Follow-up time points per outcome parameter selected for in-depth analysis. Outcome parameters were reported at variable timepoints post-injection. Timing mode and range per outcome parameters were, respectively, OCT 12 weeks (2 w–15 m), ERG 2 months (4 w–15 m), and IHC 12 weeks (1 w–15 m). OCT = optical coherence tomography, ERG = electroretinography, IHC = immunohistochemistry.
Figure 5 Follow-up time points per outcome parameter selected for in-depth analysis. Outcome parameters were reported at variable timepoints post-injection. Timing mode and range per outcome parameters were, respectively, OCT 12 weeks (2 w–15 m), ERG 2 months (4 w–15 m), and IHC 12 weeks (1 w–15 m). OCT = optical coherence tomography, ERG = electroretinography, IHC = immunohistochemistry.CC BY · PubMed Central
Figure 6 The overall effect size of adeno-associated viral vector (AAV)-mediated gene augmentation therapy on a-wave amplitudes with integrated dosage subgroup analysis. The studies included in this meta-analysis were assigned study IDs according to First Author Publication year, and experimental groups within one publication are distinguished by labeling them a through z. The studies included in this meta-analysis were Bush2016 [85], Scruggs2022 [88], Min2005 [77], and Marangoni2017 [87]. The results are staggered per subgroup (total dose smaller than 4 × 109 viral genomes/eye (vg/eye) and larger than 4 × 109 vg/eye). The black circles represent the overall subgroup effect size, and the green diamond represents the overall weighted effect size. The black dashed line indicates the null effect. The left side of the null effect line favors the control, whereas the right side of the null effect line favors treatment. The overall effect size (0.75 [0.56, 0.94]) was computed with a random effects model and is represented by a green diamond and dashed line. Included studies were assessed for homogeneity with a Chi-square test and were not found to be highly heterogeneous (I2 = 17.1%). SMD = standardized mean difference, CI = confidence interval.
Figure 6 The overall effect size of adeno-associated viral vector (AAV)-mediated gene augmentation therapy on a-wave amplitudes with integrated dosage subgroup analysis. The studies included in this meta-analysis were assigned study IDs according to First Author Publication year, and experimental groups within one publication are distinguished by labeling them a through z. The studies included in this meta-analysis were Bush2016 [85], Scruggs2022 [88], Min2005 [77], and Marangoni2017 [87]. The results are staggered per subgroup (total dose smaller than 4 × 109 viral genomes/eye (vg/eye) and larger than 4 × 109 vg/eye). The black circles represent the overall subgroup effect size, and the green diamond represents the overall weighted effect size. The black dashed line indicates the null effect. The left side of the null effect line favors the control, whereas the right side of the null effect line favors treatment. The overall effect size (0.75 [0.56, 0.94]) was computed with a random effects model and is represented by a green diamond and dashed line. Included studies were assessed for homogeneity with a Chi-square test and were not found to be highly heterogeneous (I2 = 17.1%). SMD = standardized mean difference, CI = confidence interval.CC BY · PubMed Central
Figure 7 The overall weighted effect size of adeno-associated viral vector (AAV)-mediated gene augmentation therapy on the b-wave amplitude. The studies included in this meta-analysis were assigned study IDs according to First Author Publication year, and experimental groups within one publication are distinguished by labeling them a through z. The studies included in this analysis were Min2005 [77], Molday2006 [78], Janssen2008 [80], Byrne2014 [54], Bush2016 [85], Marangoni2017 [87], and Scruggs2022 [88]. The standardized mean differences (SMDs) with 95% confidence intervals (CI) of each experimental group are displayed in a forest plot. The dashed black line represents no treatment effect. Values left of the null effect line favor control, whereas values right of the null effect line favors treatment. The overall effect size (1.44 [1.11, 1.77]) was computed with a random-effects model and is represented by a green diamond and dashed line. Included studies were assessed for homogeneity with a Chi-square test and were found to be highly heterogeneous (I2 = 76.5%).
Figure 7 The overall weighted effect size of adeno-associated viral vector (AAV)-mediated gene augmentation therapy on the b-wave amplitude. The studies included in this meta-analysis were assigned study IDs according to First Author Publication year, and experimental groups within one publication are distinguished by labeling them a through z. The studies included in this analysis were Min2005 [77], Molday2006 [78], Janssen2008 [80], Byrne2014 [54], Bush2016 [85], Marangoni2017 [87], and Scruggs2022 [88]. The standardized mean differences (SMDs) with 95% confidence intervals (CI) of each experimental group are displayed in a forest plot. The dashed black line represents no treatment effect. Values left of the null effect line favor control, whereas values right of the null effect line favors treatment. The overall effect size (1.44 [1.11, 1.77]) was computed with a random-effects model and is represented by a green diamond and dashed line. Included studies were assessed for homogeneity with a Chi-square test and were found to be highly heterogeneous (I2 = 76.5%).CC BY · PubMed Central
Figure 8 The effect sizes of adeno-associated viral vector (AAV)-mediated gene augmentation therapy on the b-wave amplitude for subgroups mouse model, delivery method, dose, age at injection, and follow-up time point. The black dashed line indicates the null effect. Values left of the null effect line favor the control, whereas values right of the null effect line favor the treatment. The overall effect size (1.44 [1.11, 1.77]) was computed with a random-effects model and is represented by a green diamond and dashed line. The between-study heterogeneity was high (I2 = 76.5%), and therefore these subgroup analyses serve for orientational purposes only. Rs1h = retinoschisin, KO = knock-out, IVI = intravitreal injection, SRI = subretinal injection, M = months of age, MPI = months post-injection, SMD = standardized mean difference, CI = confidence interval.
Figure 8 The effect sizes of adeno-associated viral vector (AAV)-mediated gene augmentation therapy on the b-wave amplitude for subgroups mouse model, delivery method, dose, age at injection, and follow-up time point. The black dashed line indicates the null effect. Values left of the null effect line favor the control, whereas values right of the null effect line favor the treatment. The overall effect size (1.44 [1.11, 1.77]) was computed with a random-effects model and is represented by a green diamond and dashed line. The between-study heterogeneity was high (I2 = 76.5%), and therefore these subgroup analyses serve for orientational purposes only. Rs1h = retinoschisin, KO = knock-out, IVI = intravitreal injection, SRI = subretinal injection, M = months of age, MPI = months post-injection, SMD = standardized mean difference, CI = confidence interval.CC BY · PubMed Central
Figure 9 The overall weighted effect size of AAV-mediated gene augmentation therapy on the ratio between the b- and a-wave amplitudes (b/a-ratio). The studies included in this meta-analysis were assigned study IDs according to First Author Publication year, and experimental groups within one publication are distinguished by labeling them a through z. The studies included in this analysis were Bush2016 [85], Park2009 [82], and Marangoni2017 [87]. The results are staggered per subgroup (total dose smaller than 4 × 109 viral genomes/eye (vg/eye) and larger than 4 × 109 vg/eye). The black circles represent the overall subgroup effect size, and the green diamond represents the overall weighted effect size. The black dashed line indicates the null effect. Values left of the null effect line favor control, whereas values right of the null effect line favors treatment. The overall effect size (1.08 [0.42, 1.74]) was computed with a random-effects model and is represented by a green diamond and dashed line. The black circles indicate the overall subgroup effect size. A Chi-square test of homogeneity revealed high levels of between-study heterogeneity (I2 = 90.7%). SMD = standardized mean difference, CI = confidence interval.
Figure 9 The overall weighted effect size of AAV-mediated gene augmentation therapy on the ratio between the b- and a-wave amplitudes (b/a-ratio). The studies included in this meta-analysis were assigned study IDs according to First Author Publication year, and experimental groups within one publication are distinguished by labeling them a through z. The studies included in this analysis were Bush2016 [85], Park2009 [82], and Marangoni2017 [87]. The results are staggered per subgroup (total dose smaller than 4 × 109 viral genomes/eye (vg/eye) and larger than 4 × 109 vg/eye). The black circles represent the overall subgroup effect size, and the green diamond represents the overall weighted effect size. The black dashed line indicates the null effect. Values left of the null effect line favor control, whereas values right of the null effect line favors treatment. The overall effect size (1.08 [0.42, 1.74]) was computed with a random-effects model and is represented by a green diamond and dashed line. The black circles indicate the overall subgroup effect size. A Chi-square test of homogeneity revealed high levels of between-study heterogeneity (I2 = 90.7%). SMD = standardized mean difference, CI = confidence interval.CC BY · PubMed Central
Figure 10 The funnel plots of the meta-analyzed studies. The blue dots indicate standardized mean differences (SMD) of primary studies; the green dots indicate missing studies. The black lines indicate overall effect size, and the dashed lines indicate the 95% confidence intervals (CI). (A) The funnel plot for b-wave amplitude. A trim-and-fill analysis predicted missing studies. (B) The funnel plot for a-wave amplitude. A trim-and-fill analysis predicted missing studies. (C) The funnel plot for the ratio between the b- and a-wave amplitudes (b/a-ratio). Trim-and-fill analysis predicted no missing studies.
Figure 10 The funnel plots of the meta-analyzed studies. The blue dots indicate standardized mean differences (SMD) of primary studies; the green dots indicate missing studies. The black lines indicate overall effect size, and the dashed lines indicate the 95% confidence intervals (CI). (A) The funnel plot for b-wave amplitude. A trim-and-fill analysis predicted missing studies. (B) The funnel plot for a-wave amplitude. A trim-and-fill analysis predicted missing studies. (C) The funnel plot for the ratio between the b- and a-wave amplitudes (b/a-ratio). Trim-and-fill analysis predicted no missing studies.CC BY · PubMed Central
Figure 11 The classification of alternative delivery and non-viral delivery methods. The first classification is alternative delivery and non-viral delivery methods. In the former, the exosome-associated adeno-assiocated viral vectors (AAVs) are classified [93]. Within the non-viral methods category, a second classification can be made: chemical and physical methods. The physical methods contain the electroporation method [58], while the chemical methods can be divided into organic (solid lipid nanoparticles [63,95]) or inorganic (dual supramolecules nanoparticles [96] and carboxylated nanodiamonds [97]) vectors. In each category, a schematic representation of the vectors used for RS1 or gene editing constructs delivery is included to illustrate the building blocks used in each vector. Dual supramolecular nanoparticle and carboxylated nanodiamond representations have been adapted from Chou et al. and Yang et al., respectively [96,97]. Outlined with a yellow line are the studies designed for gene augmentation, whereas those designed for gene editing are marked with a green line. XLRS = X-linked juvenile retinoschisis, RS1 = retinoschisin, ad = adamantane-grafted, PEG = polyethylene glycol, TAT = adenosine-5’-rp-alpha-thio-triphosphate, CD-PEI = carbon dot-polyethylenimine, GFP = green fluorescent protein, sgRNA = single guide RNA.
Figure 11 The classification of alternative delivery and non-viral delivery methods. The first classification is alternative delivery and non-viral delivery methods. In the former, the exosome-associated adeno-assiocated viral vectors (AAVs) are classified [93]. Within the non-viral methods category, a second classification can be made: chemical and physical methods. The physical methods contain the electroporation method [58], while the chemical methods can be divided into organic (solid lipid nanoparticles [63,95]) or inorganic (dual supramolecules nanoparticles [96] and carboxylated nanodiamonds [97]) vectors. In each category, a schematic representation of the vectors used for RS1 or gene editing constructs delivery is included to illustrate the building blocks used in each vector. Dual supramolecular nanoparticle and carboxylated nanodiamond representations have been adapted from Chou et al. and Yang et al., respectively [96,97]. Outlined with a yellow line are the studies designed for gene augmentation, whereas those designed for gene editing are marked with a green line. XLRS = X-linked juvenile retinoschisis, RS1 = retinoschisin, ad = adamantane-grafted, PEG = polyethylene glycol, TAT = adenosine-5’-rp-alpha-thio-triphosphate, CD-PEI = carbon dot-polyethylenimine, GFP = green fluorescent protein, sgRNA = single guide RNA.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 120 references

Research works printed but not linked: 1

  1. Haas, 1898, Ueber das Zusammenvorkommen von Veraenderungen der Retina und Choroidea, Arch. Augenheilkd., 37, 343

Cited by

See all 15

Metadata

Authors
van der Veen, I., Heredero Berzal, A., Koster, C., ten Asbroek, A. L. M. A., Bergen, A. A., & Boon, C. J. F.
Affiliations
  • Department of Ophthalmology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
  • Leiden University (NL)
Corresponding author
Boon, Camiel J. F.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2024-01-19
Volume
25
Issue
2
Pages
1267
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4391107036
Cited by
14
References
120
Citations by year
2026: 4 · 2025: 8 · 2024: 2
FWCI
0.57
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (acceptedVersion, cc-by)
Funders
NWO-ALW (Nederlandse Organisatie voor Wetenschappelijk Onderzoek-Aard en Levenswetenschappen) (09150171910048)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
X-linked retinoschisis, retinoschisin, RS1, gene therapy, gene augmentation therapy, adeno-associated virus vectors, viral vectors, non-viral gene delivery, rodent models, cell-based models, electroretinogram, retinal function, risk of bias assessment
MeSH terms
Animals, Electroretinography, Eye Proteins, Humans, Male, Mutation, Retina, Genetic Therapy, Retinoschisis, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Road towards Gene Therapy for X-Linked Juvenile Retinoschisis: A Systematic Review of Preclinical Gene Therapy in Cell-Based and Rodent Models of XLRS. https://app.cochat.ai/papers/10.3390/ijms25021267
The paper
van der Veen, I., Heredero Berzal, A., Koster, C., ten Asbroek, A. L. M. A., Bergen, A. A., & Boon, C. J. F. (2024). The Road towards Gene Therapy for X-Linked Juvenile Retinoschisis: A Systematic Review of Preclinical Gene Therapy in Cell-Based and Rodent Models of XLRS. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25021267

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.